Completed OBSERVATIONAL NCT00879801

Genetic Physiopathology and Evolution of Type 2 Diabetes (GENFIEV)

Evaluation of Genetic, Biochemical and Clinical Determinants of Type 2 Diabetes Progression in Subjects at High Risk

Sponsor: Eli Lilly and Company

Updated 9 times since 2017 Last updated: Apr 9, 2009 Started: Jan 31, 2003 Primary completion: Dec 31, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Pre-Diabetes and is currently completed. Eli Lilly and Company leads this study, which shows 9 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2021 — Jul 2024 [monthly]

Completed
Jan 2021 — Dec 2021 [monthly]

Completed
Nov 2020 — Jan 2021 [monthly]

Completed

▶ Show 4 earlier versions

May 2018 — Nov 2020 [monthly]

Completed
Apr 2018 — May 2018 [monthly]

Completed

Phase: NA → None
Aug 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Aug 2017 [monthly]

Completed NA

First recorded

Jan 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company
Italian Society of Diabetology
University of Pisa

Data source: University of Pisa

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pisa, Italy